Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI – Get Rating) major shareholder Global Strategic Fund I. Venbio sold 17,600 shares of the firm’s stock in a transaction that occurred on Monday, May 9th. The shares were sold at an average price of $10.37, for a total transaction of $182,512.00. Following the completion of the transaction, the insider now owns 2,448,481 shares of the company’s stock, valued at approximately $25,390,747.97. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Checkmate Pharmaceuticals stock remained flat at $$10.38 during mid-day trading on Monday. 122,225 shares of the company’s stock traded hands, compared to its average volume of 130,681. Checkmate Pharmaceuticals, Inc. has a 52-week low of $2.00 and a 52-week high of $10.48. The firm’s 50 day moving average price is $5.11 and its two-hundred day moving average price is $3.88. The firm has a market capitalization of $228.57 million, a PE ratio of -3.65 and a beta of -4.84.
Checkmate Pharmaceuticals (NASDAQ:CMPI – Get Rating) last released its quarterly earnings results on Tuesday, March 29th. The company reported ($0.62) earnings per share (EPS) for the quarter. On average, research analysts expect that Checkmate Pharmaceuticals, Inc. will post -3.14 earnings per share for the current year.
A number of research analysts recently issued reports on the stock. BTIG Research lowered shares of Checkmate Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, April 20th. Zacks Investment Research upgraded shares of Checkmate Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 3rd.
An institutional investor recently bought a new position in Checkmate Pharmaceuticals stock. Millennium Management LLC acquired a new stake in Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI – Get Rating) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 40,422 shares of the company’s stock, valued at approximately $241,000. Millennium Management LLC owned approximately 0.19% of Checkmate Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 74.56% of the company’s stock.
Checkmate Pharmaceuticals Company Profile (Get Rating)
Checkmate Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.
Receive News & Ratings for Checkmate Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.